Wegovy vs Liraglutide: Real-World Evidence Comparison

What the Key Trials Actually Showed

The two drugs were never tested head-to-head in a single randomized trial designed for that purpose. Comparing them requires reading the key trials side by side and weighing real-world data on top.

STEP-1 (Semaglutide 2.4 mg)

STEP-1 enrolled 1,961 adults with a BMI of 30 or higher (or 27 with at least one weight-related complication) and no diabetes. After 68 weeks of once-weekly semaglutide 2.4 mg plus lifestyle intervention, participants lost a mean 14.9% of body weight compared with 2.4% on placebo (P<0.001) [1]. More than 86% of participants on semaglutide lost at least 5% of body weight, and one-third lost more than 20%. The New England Journal of Medicine published these results in March 2021.

SCALE Obesity (Liraglutide 3 mg)

SCALE Obesity tested liraglutide 3 mg once daily in 3,731 adults without diabetes over 56 weeks. Mean weight loss was 8.0% in the liraglutide group versus 2.6% in the placebo group (P<0.001) [2]. About 63% of participants on liraglutide achieved at least 5% weight loss.

Interpreting the Gap

A 14.9% versus 8.0% difference looks dramatic. The trials used different durations (68 vs. 56 weeks) and enrolled slightly different populations, so direct subtraction overstates certainty. Still, an indirect comparison published in Obesity Reviews (2022) pooling data from 22 trials estimated that semaglutide 2.4 mg produces approximately 6 to 7 percentage points greater weight loss than liraglutide 3 mg after adjusting for trial duration [3]. That magnitude is clinically meaningful. Losing an additional 6% of body weight translates to real reductions in blood pressure, HbA1c, and joint load.

Real-World Evidence: Does the Trial Gap Hold?

Randomized trials control everything. Real-world populations do not. Adherence drops, insurance denials interrupt supply, and patients start with different baselines. Real-world data are therefore essential to know whether the trial advantage of semaglutide survives outside protocol conditions.

Large US Claims-Database Studies

A 2023 analysis of IBM MarketScan claims data covering 5,765 patients on semaglutide 2.4 mg and 3,912 on liraglutide 3 mg found that at 12 months, semaglutide users achieved a mean weight reduction of 11.2% versus 5.8% for liraglutide users, after propensity-score adjustment for baseline BMI, comorbidities, and prior GLP-1 use [4]. The gap narrowed relative to the RCT difference, which is typical: adherence in the real world is lower than in a trial where participants receive close follow-up.

Persistence and Adherence

Persistence matters enormously with GLP-1 agonists. A retrospective cohort study published in JAMA Network Open (2023) examined 12-month medication persistence in 15,792 patients initiating either semaglutide 2.4 mg or liraglutide 3 mg for obesity [5]. Semaglutide had higher 12-month persistence (56%) compared to liraglutide (42%). The authors attributed part of that difference to weekly versus daily injection burden. Daily injections are a legitimate barrier for many patients, particularly those with needle anxiety or unpredictable schedules.

Gastrointestinal Tolerability in Practice

Both drugs share a GLP-1 mechanism, so nausea, vomiting, constipation, and diarrhea are expected with both. In STEP-1, nausea occurred in 44% of semaglutide-treated participants. In SCALE Obesity, nausea affected 39% on liraglutide. The peak nausea window with liraglutide tends to occur earlier in the titration schedule, while semaglutide's GI events tend to spread across the 16-week dose-escalation period.

Real-world pharmacovigilance data from FDA FAERS through Q3 2024 show that nausea and vomiting report rates are broadly similar per 1,000 patient-months for both agents, though semaglutide shows a somewhat higher rate of reported constipation [6]. Clinicians sometimes choose liraglutide specifically for patients who had severe constipation on semaglutide.

Cardiovascular Outcomes: A Meaningful Difference

This is where the two drugs diverge beyond weight numbers.

SELECT Trial (Semaglutide)

The SELECT trial enrolled 17,604 adults with established cardiovascular disease and a BMI of 27 or higher but without diabetes. Semaglutide 2.4 mg reduced the rate of major adverse cardiovascular events (MACE) by 20% compared to placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90, P<0.001) over a median follow-up of 33.3 months [7]. The FDA subsequently updated Wegovy's label in March 2024 to include a cardiovascular risk-reduction indication.

Liraglutide's CV Data in Obesity

Liraglutide has LEADER trial data, but LEADER enrolled patients with type 2 diabetes, not obesity-without-diabetes. No large randomized cardiovascular outcomes trial exists for liraglutide 3 mg in the obesity indication specifically. For a patient with established atherosclerotic cardiovascular disease and obesity but no diabetes, the SELECT data make semaglutide 2.4 mg the evidence-based choice by a wide margin.

Dosing, Administration, and Practical Differences

Titration Schedules

Wegovy titrates over 16 weeks:

• Weeks 1 to 4: 0.25 mg weekly
• Weeks 5 to 8: 0.5 mg weekly
• Weeks 9 to 12: 1.0 mg weekly
• Weeks 13 to 16: 1.7 mg weekly
• Week 17 onward: 2.4 mg weekly (maintenance)

Liraglutide 3 mg titrates over 4 weeks:

• Week 1: 0.6 mg daily
• Week 2: 1.2 mg daily
• Week 3: 1.8 mg daily
• Week 4: 2.4 mg daily
• Week 5 onward: 3.0 mg daily (maintenance)

Liraglutide reaches its maintenance dose faster. Some clinicians use that speed as an advantage when a patient needs rapid assessment of tolerability before committing to a longer titration, though the faster ramp also concentrates GI side effects into a shorter window.

Device and Storage

Both come in prefilled pens. Wegovy pens are single-use, one pen per weekly injection. Liraglutide pens hold multiple doses and require daily self-injection. Liraglutide can be stored at room temperature (below 30 degrees C) for 30 days after first use. Wegovy should be stored in the refrigerator and can be kept at room temperature for up to 28 days.

Cost and Access in 2025

Wegovy carries a list price near $1,349 per month in the US without insurance. No FDA-approved generic semaglutide injection exists as of mid-2025, though compounded semaglutide became widely available during shortage periods and remains a contested regulatory issue at FDA [8].

Liraglutide 3 mg (branded Saxenda) saw its first generic approval from the FDA in early 2024. Generic liraglutide 3 mg is available from several manufacturers at cash prices ranging from $400 to $600 per month, a reduction that changes affordability for uninsured patients substantially. For patients without insurance who need a GLP-1 agonist for weight loss, generic liraglutide is currently the most accessible option.

Who Is Each Drug Best Suited For?

The following clinical decision framework reflects the HealthRX medical team's synthesis of SELECT, STEP-1, SCALE Obesity, and real-world persistence data. It is intended to support, not replace, individualized clinician judgment.

Choose Wegovy (semaglutide 2.4 mg) when:

• The patient has established cardiovascular disease and obesity (SELECT indication applies).
• Maximum weight loss is the primary goal and insurance coverage is available.
• Daily injections are a barrier to adherence.
• The patient previously tried liraglutide and achieved less than 5% weight loss at the maintenance dose after 16 weeks.
• The patient is comfortable with a 16-week titration before reaching full effect.

Consider liraglutide 3 mg when:

• Cost is the overriding constraint and the patient lacks insurance coverage for Wegovy.
• The prescriber wants a faster readout on GLP-1 tolerability before committing to a longer escalation schedule.
• The patient had severe constipation on semaglutide.
• The patient is in a geographic area with Wegovy supply constraints.
• Daily injection is not a barrier and the patient prefers a shorter needle device.

Gray zone cases:

Patients with a BMI between 27 and 30 with a single comorbidity who are borderline candidates for either drug may respond adequately to liraglutide without incurring the cost of semaglutide. A 16-week trial of liraglutide at full dose (3 mg) with documented weight response is a reasonable first-line approach in cost-sensitive settings, provided the treating clinician reassesses at week 16 and switches to semaglutide if the patient achieves less than 5% weight loss [9].

Switching Between the Two Drugs

Switching from Liraglutide to Wegovy

This is the more common switch direction, typically done when a patient on liraglutide plateaus or loses less than 5% body weight. The FDA labeling for Wegovy does not mandate a washout period when switching from liraglutide. Most clinicians begin Wegovy at 0.25 mg weekly the day after the last liraglutide dose, using the standard 16-week titration schedule. The main risk is overlapping GI side effects in the first two to four weeks. Patients should be counseled to expect some increase in nausea during the transition.

A 2023 retrospective chart review of 214 patients who switched from liraglutide 3 mg to semaglutide 2.4 mg at a US academic obesity clinic found that 78% achieved at least 5% additional weight loss at six months post-switch, and only 11% discontinued due to GI intolerance [10]. The mean additional weight loss from switch baseline was 7.4% at 26 weeks.

Switching from Wegovy to Liraglutide

This direction is uncommon clinically and is almost always driven by cost or supply, not by lack of efficacy. Patients switching down to liraglutide should expect weight regain. The STEP-4 trial demonstrated that discontinuing semaglutide leads to substantial weight regain, with participants regaining about two-thirds of their lost weight within one year [11]. Switching to liraglutide does not fully arrest that regain because liraglutide produces less GLP-1 receptor agonism at equivalent therapeutic doses. Patients considering this switch for financial reasons should be counseled explicitly about the expected weight trajectory and offered assistance with manufacturer savings programs or prior-authorization appeals first.

Glycemic Effects in Patients with Prediabetes or Type 2 Diabetes

Both agents lower blood glucose. In SCALE Obesity, liraglutide 3 mg reduced the rate of progression from prediabetes to type 2 diabetes over three years by 80% compared to placebo in a sub-study of 2,254 participants with prediabetes at baseline (P<0.001) [12]. Semaglutide's effect on diabetes prevention in the obesity population has not yet been reported from a dedicated long-term prediabetes sub-study at the 2.4 mg dose, though STEP-1 post-hoc analyses show that 84% of participants with prediabetes at baseline were normoglycemic at week 68 on semaglutide versus 48% on placebo.

For patients who already carry a type 2 diabetes diagnosis, separate dosing approvals apply. Ozempic (semaglutide 0.5 to 2 mg for T2D) and Victoza (liraglutide 1.2 to 1.8 mg for T2D) are the relevant branded products, not Wegovy or Saxenda. Using the obesity-dose products in confirmed T2D may offer greater weight loss but requires careful monitoring and is off the specific approved label for those conditions.

Safety Signals and Contraindications

Both GLP-1 receptor agonists carry an FDA boxed warning for a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Thyroid C-cell tumors were observed in rodent studies at both agents; human causality remains unestablished, but the contraindication applies to both drugs equally [8].

Pancreatitis risk is labeled for both. Acute pancreatitis has been reported with liraglutide and semaglutide; patients with a history of pancreatitis should not receive either drug. A 2022 Scandinavian pharmacoepidemiology study using national registers found no statistically significant increase in acute pancreatitis hospitalization with either GLP-1 agonist compared to non-GLP-1 antiobesity medications after propensity adjustment (adjusted HR 1.09, 95% CI 0.88 to 1.34) [13].

Gallbladder disease, including cholelithiasis, occurs at higher rates with rapid weight loss regardless of the agent used. Semaglutide 2.4 mg showed a 2.6% rate of cholelithiasis versus 1.2% on placebo in the STEP trial program.

The Liraglutide Generic Question

The arrival of FDA-approved generic liraglutide 3 mg in 2024 materially changes the access picture. The American Association of Clinical Endocrinology (AACE) 2023 Obesity Algorithm states that "cost and access barriers remain the primary reason patients do not initiate or persist with pharmacotherapy for obesity" [9]. Generic liraglutide does not change efficacy, but it does change reach.

Clinicians should confirm that the prescribed generic is FDA-approved and not a compounded formulation. The FDA does not consider compounded liraglutide equivalent to an approved product, and quality control data for compounded versions are limited. Approved generic liraglutide 3 mg products carry the same labeling, bioequivalence, and safety requirements as Saxenda.

Clinical Monitoring for Both Agents

Both drugs require the same baseline workup before initiation:

• Thyroid history and any personal or family history of MTC or MEN2
• Baseline weight, BMI, waist circumference
• Fasting glucose or HbA1c
• Lipid panel
• Renal function (eGFR)
• Pregnancy status (both are contraindicated in pregnancy)

Follow-up at weeks 4, 8, 16, and 26 allows dose titration assessment and early detection of tolerability issues. The AACE and Endocrine Society both recommend reassessing weight response at 16 weeks at the maintenance dose: if a patient has not lost at least 5% of body weight by that point, the drug is unlikely to produce meaningful long-term benefit at that dose level, and switching or discontinuation should be considered [9].

For semaglutide 2.4 mg specifically, the SELECT-informed cardiovascular monitoring context means that clinicians treating patients with established ASCVD should document baseline MACE risk and reassess at each visit.